Neuropace
NPCE
25 hedge funds and large institutions have $176M invested in Neuropace in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
124% more capital invested
Capital invested by funds: $78.6M → $176M (+$97.3M)
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
14% more funds holding
Funds holding: 22 → 25 (+3)
1.01% more ownership
Funds ownership: 68.88% → 69.89% (+1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.66M |
| 2 |
KLC
Kent Lake Capital
Reno,
Nevada
|
+$2.49M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
+$829K |
| 4 |
Morgan Stanley
New York
|
+$239K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$227K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.03M |
| 2 |
Millennium Management
New York
|
-$2.6M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.97K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$872 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$404 |
NPCE Hedge Fund Activity: Q3 2023 in Review
25 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q3 2023, worth a combined $176M — up 124% from $78.6M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NPCE positions and 1 closed out — a net gain of 4 holders — while 10 added to existing stakes and 5 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $4.66M. The largest seller was Fidelity Investments, cutting an estimated $3.03M.
- 25 institutional investors held Neuropace (NPCE) as of Q3 2023, up from 22 in Q2 2023.
- Funds reported $176M of Neuropace stock for Q3 2023, up 124% quarter-over-quarter.
- 5 funds opened new Neuropace positions in Q3 2023 and 1 closed out, a net change of +4 holders.
- The largest Neuropace buyer in Q3 2023 was Nantahala Capital Management, an estimated $4.66M added.
- The largest Neuropace seller in Q3 2023 was Fidelity Investments, an estimated $3.03M sold.
Based on aggregated 13F filings for Q3 2023.